All In Biotech

Drug Trial Radar · NCT06525636

A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia

A Multicenter, Open-label, Phase 1/2, Dose-escalation and Subsequent Safety Extension Study of Subcutaneous KK8123 in Adult Patients With X-linked Hypophosphatemia

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

39

Planned (sponsor's estimate)

Start

Oct 9, 2024

Primary completion

Jun 14, 2030

Study completion Jun 14, 2030

Sponsor

Lead sponsor
Kyowa Kirin Co., Ltd.Industry
Sponsor type
Industry
Collaborators
Kyowa Kirin, Inc.
First posted
Jul 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A first-in-human study of KK8123 in adults with X-linked hypophosphatemia.

Conditions

  • X-linked Hypophosphatemia

Interventions

  • KK8123Drug

    Subcutaneous administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of participants with TEAEsTime frame: For up to 48 weeks.
  2. Part 1: Percentage of participants with TEAEsTime frame: For up to 48 weeks.
  3. Part 2: Number of participants with TEAEsTime frame: For up to 48 weeks.
  4. Part 2: Percentage of participants with TEAEsTime frame: For up to 48 weeks.
  5. Part 1: Change from baseline for haematology laboratories valuesTime frame: For up to 48 weeks.
  6. Part 2: Change from baseline for haematology laboratories valuesTime frame: For up to 48 weeks.
  7. Part 1: Change from baseline for clinical chemistry laboratories valuesTime frame: For up to 48 weeks.
  8. Part 2: Change from baseline for clinical chemistry laboratories valuesTime frame: For up to 48 weeks.
  9. Part 1: Change from baseline in continuous variables for FSHTime frame: For up to 48 weeks.
  10. Part 2: Change from baseline in continuous variables for FSHTime frame: For up to 48 weeks.
  11. Part 1: Change from baseline in continuous variables for estradiolTime frame: For up to 48 weeks.
  12. Part 2: Change from baseline in continuous variables for estradiolTime frame: For up to 48 weeks.
  13. Part 1: Change from baseline in continuous variables for temperatureTime frame: For up to 48 weeks.
  14. Part 2: Change from baseline in continuous variables for temperatureTime frame: For up to 48 weeks.
  15. Part 1: Change from baseline in continuous variables for pulse rateTime frame: For up to 48 weeks.
  16. Part 2: Change from baseline in continuous variables for pulse rateTime frame: For up to 48 weeks.
  17. Part 1: Change from baseline in continuous variables for respiratory rateTime frame: For up to 48 weeks.
  18. Part 2: Change from baseline in continuous variables for respiratory rateTime frame: For up to 48 weeks.
  19. Part 1: Change from baseline in continuous variables for systolic and diastolic blood pressureTime frame: For up to 48 weeks.
  20. Part 2: Change from baseline in continuous variables for systolic and diastolic blood pressureTime frame: For up to 48 weeks.
  21. Part 1: Change from baseline in continuous variables for QTTime frame: For up to 48 weeks.
  22. Part 2: Change from baseline in continuous variables for QTTime frame: For up to 48 weeks.
  23. Part 1: Change from baseline in continuous variables for QTcTime frame: For up to 48 weeks.
  24. Part 2: Change from baseline in continuous variables for QTcTime frame: For up to 48 weeks.
  25. Part 1: Change from baseline in continuous variables for QTCFTime frame: For up to 48 weeks.
  26. Part 2: Change from baseline in continuous variables for QTCFTime frame: For up to 48 weeks.
  27. Part 1: Change from baseline in continuous variables for QRSTime frame: For up to 48 weeks.
  28. Part 2: Change from baseline in continuous variables for QRSTime frame: For up to 48 weeks.
  29. Part 1: Change from baseline in continuous variables for heart rateTime frame: For up to 48 weeks.
  30. Part 2: Change from baseline in continuous variables for heart rateTime frame: For up to 48 weeks.
  31. Part 1: The presence or absence of abnormality on ectopic mineralization, any sign of left ventricular hypertrophy or heart failures before and after administration of KK8123 on EchocardiogramTime frame: For up to 48 weeks.
  32. Part 2: The presence or absence of abnormality on ectopic mineralization, any sign of left ventricular hypertrophy or heart failures before and after administration of KK8123 on EchocardiogramTime frame: For up to 48 weeks.
  33. Part 1: Before and after administration presented at each time point in categorical variables for renal ultrasoundTime frame: For up to 48 weeks.
  34. Part 2: Before and after administration presented at each time point in categorical variables for renal ultrasoundTime frame: For up to 48 weeks.
  35. Part 1: KK8123 concentrations by maximum plasma concentration (Cmax)Time frame: For up to 48 weeks.
  36. Part 2: KK8123 concentrations by maximum plasma concentration (Cmax)Time frame: For up to 48 weeks.
  37. Part 1: KK8123 concentrations by maximum serum concentration (tmax)Time frame: For up to 48 weeks.
  38. Part 2: KK8123 concentrations by maximum serum concentration (tmax)Time frame: For up to 48 weeks.
  39. Part 1: KK8123 concentrations by area under the serum concentration time curve from zero to last detectable time point (AUClast)Time frame: For up to 48 weeks.
  40. Part 2: KK8123 concentrations by area under the serum concentration time curve from zero to last detectable time point (AUClast)Time frame: For up to 48 weeks.
  41. Part 1: KK8123 concentrations by the area under the serum concentration time curve from zero to infinity (AUC00-inf)Time frame: For up to 48 weeks.
  42. Part 2: KK8123 concentrations by the area under the serum concentration time curve from zero to infinity (AUC00-inf)Time frame: For up to 48 weeks.
  43. Part 1: KK8123 concentrations by apparent volume of distribution (V/F)Time frame: For up to 48 weeks.
  44. Part 2: KK8123 concentrations by apparent volume of distribution (V/F)Time frame: For up to 48 weeks.
  45. Part 1: KK8123 concentrations by terminal half-life (t1/2)Time frame: For up to 48 weeks.
  46. Part 2: KK8123 concentrations by terminal half-life (t1/2)Time frame: For up to 48 weeks.
  47. Part 1: KK8123 concentrations by apparent clearance (CL/F)Time frame: For up to 48 weeks.
  48. Part 2: KK8123 concentrations by apparent clearance (CL/F)Time frame: For up to 48 weeks.
  49. Part 1: KK8123 concentrations by maximum plasma concentration steady state (Cmax,ss)Time frame: For up to 48 weeks.
  50. Part 2: KK8123 concentrations by maximum plasma concentration steady state (Cmax,ss)Time frame: For up to 48 weeks.
  51. Part 1: KK8123 concentrations by time to maximum serum concentration steady state (tmax,ss)Time frame: For up to 48 weeks.
  52. Part 2: KK8123 concentrations by time to maximum serum concentration steady state (tmax,ss)Time frame: For up to 48 weeks.
  53. Part 1: KK8123 concentrations over time by area under the serum concentration curve within a dosing interval at steady state (AUCtau,ss)Time frame: For up to 48 weeks.
  54. Part 2: KK8123 concentrations over time by area under the serum concentration curve within a dosing interval at steady state (AUCtau,ss)Time frame: For up to 48 weeks.
  55. Part 1: KK8123 concentrations by time to steady stateTime frame: For up to 48 weeks.
  56. Part 2: KK8123 concentrations by time to steady stateTime frame: For up to 48 weeks.
  57. Part 1: KK8123 concentrations by accumulation ratioTime frame: For up to 48 weeks.
  58. Part 2: KK8123 concentrations by accumulation ratioTime frame: For up to 48 weeks.
  59. Part 1: To evaluate the effect of single and multiple SC administrations of KK8123 on serum phosphorus levelsTime frame: For up to 48 weeks.
  60. Part 2: To evaluate the effect of multiple SC administrations of KK8123 on serum phosphorus levelsTime frame: For up to 48 weeks.

Locations

10 sites in 5 countries. Site status is shown where the registry gives one.

  • University of California - San Francisco

    San Francisco, California · Recruiting

  • Yale Center for XLH/ Yale University School of Medicine

    New Haven, Connecticut · Recruiting

  • Indiana University School of Medicine University Hospital

    Indianapolis, Indiana · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Not yet recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

  • Bone Research and Education Center

    Oakville, Ontario, Canada · Recruiting

  • Hoptial Bictre

    Le Kremlin-Bicêtre, Paris, France · Recruiting

  • Institute of Osteology and Biomechanics (IOBM)

    Hamburg, Germany · Recruiting

  • Universitaetsklinikum Wurzburg

    Würzburg, Germany · Recruiting

  • Hospital Universitario La Paz

    Madrid, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.